Revolution Medicines, Inc. provided earnings guidance for the year ended December 31, 2024. For the period, the company expects its net loss for the year ended December 31, 2024 to be between $560 million and $600 million, which includes estimated non-cash stock-based compensation expense of approximately $70 million to $80 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
46 USD | +1.91% |
|
+16.22% | +60.39% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+60.39% | 7.59B | |
+22.15% | 46.56B | |
+45.04% | 41.67B | |
-2.37% | 41.16B | |
+33.84% | 32.4B | |
-6.35% | 28.1B | |
+20.42% | 28.18B | |
+48.83% | 14.52B | |
+45.00% | 13.74B | |
+0.06% | 12.17B |
- Stock Market
- Equities
- RVMD Stock
- News Revolution Medicines, Inc.
- Revolution Medicines, Inc. Provides Earnings Guidance for the Year Ended December 31, 2024